BiondVax Presenting at BIO CEO & Investor Conference
02 févr. 2023 14h15 HE
|
BiondVax Pharmaceuticals Ltd.
JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing...
GeoVax to Present at the 2023 BIO CEO & Investor Conference
26 janv. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
13 déc. 2021 08h00 HE
|
Galectin Therapeutics Inc.
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal...
Galectin Therapeutics to Present at 4th Global NASH Congress
27 avr. 2021 09h28 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
04 mars 2021 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes,...
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
11 déc. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
09 nov. 2020 08h00 HE
|
Galectin Therapeutics Inc.
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 ...
Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
29 sept. 2020 12h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
10 sept. 2020 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
02 sept. 2020 08h00 HE
|
Galectin Therapeutics Inc.
Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa...